<DOC>
	<DOCNO>NCT02456584</DOCNO>
	<brief_summary>This randomize , multi-center , parallel-group study evaluate pharmacodynamics ( PD ) Medroxyprogesterone Acetate ( MPA ) single subcutaneous ( SC ) injection 150 mg/mL 300 mg/2 mL Depo-Provera CI abdomen woman reproductive age confirm ovulatory baseline cycle .</brief_summary>
	<brief_title>Pharmacodynamics Pharmacokinetics Study Existing DMPA Contraceptive Methods</brief_title>
	<detailed_description>This randomize , multi-center , parallel-group study primary objective evaluate pharmacodynamics ( PD ) Medroxyprogesterone Acetate ( MPA ) single subcutaneous ( SC ) injection 150mg/mL 300mg/2mL Depo-Provera CI abdomen woman reproductive age confirm ovulatory baseline cycle . Secondary study objective : - To evaluate compare pharmacokinetics ( PK ) MPA single SC injection 150mg/mL 300mg/2mL Depo-Provera CI two injection Depo-subQ 104 administer 3 month apart - To evaluate relationship serum MPA concentration suppression ovulation - To evaluate compare safety , tolerability acceptability SC injection DMPA different frequency , dos volume</detailed_description>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>inclusion Women may include study meet follow criterion : good general health age 18 40 year , inclusive willing provide inform consent follow study requirement pregnant desire become pregnant next 24 month regular menstrual cycle ( 24 35 day ) confirm ovulation serum P ≥ 4.7 ng/mL two consecutive sample pretreatment phase study low risk pregnancy ( e.g. , sterilize , exclusively sex partnership , monogamous relationship vasectomize partner , abstinent , use nonhormonal IUD condom ) body mass index 18.0 35.0 hemoglobin ≥10.5 g/L exclusion Women exclude participate study meet follow criterion : medical contraindication DMPA use use follow medication within 1 month prior enrollment : investigational drug prohibit drug ( per protocol ) oral contraceptive LNG IUS implant use DMPA past 12 month use combine injectable contraceptive past 6 month recent pregnancy ( within 3 month ) current lactation ongoing anticipate use prohibit drug ( per protocol ) know sensitivity MPA plan move another location next 18 month condition ( social medical ) opinion site investigator would make study participation unsafe , would interfere adherence study requirement complicate data interpretation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>depot medroxyprogesterone acetate ( DMPA )</keyword>
	<keyword>confidence interval ( CI )</keyword>
	<keyword>Subcutaneous ( sub-Q )</keyword>
	<keyword>Intrauterine device ( IUD )</keyword>
	<keyword>Levonorgestrel ( LNG )</keyword>
	<keyword>intrauterine system ( IUS )</keyword>
</DOC>